Phase 2 Leukaemia Trial, Recruiting NCT06055621 Sponsor: Institut Paoli-Calmettes Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06055621
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of blood cancer called AML (acute myeloid leukemia), except for two particular subtypes known as Philadelphia chromosome-positive AML and acute promyelocytic leukemia (AML M3)
  • People aged 18 or older
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scale called the ECOG scale (score of 3 or below) (confirm with trial site)
  • People whose AML has not responded to a specific combination treatment called venetoclax plus azacitidine (VEN-AZA) after at least two rounds of that treatment
  • People who have signed a form confirming they understand and agree to take part in the trial
  • People who are covered by a social security or health insurance system (this requirement appears to relate to the French healthcare system) (confirm with trial site)

Who may not be able to join:

  • People whose condition means a doctor could prescribe them another targeted therapy that already has official regulatory approval
  • People whose cancer has spread to the brain or spinal cord
  • People who have heart failure
  • People who have liver failure
  • People who have kidney failure
  • People who have a medical reason they cannot take a drug called dasatinib
  • People who have HIV with a detectable viral load, or who have active Hepatitis B or Hepatitis C
  • People who are pregnant or breastfeeding
  • Women of childbearing age who are not using an effective form of contraception
  • People who are in an emergency medical situation or who are unable to give informed consent
  • People who are under a legal protection arrangement, such as guardianship or curatorship
  • People who are unable to attend the required medical follow-up appointments due to geographic, social, or psychological reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +33491223778

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institut Paoli-Calmettes
Registry
ClinicalTrials.gov
Start date
22 May 2024
Est. completion
8 July 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

tumor response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov